Anticipated Financial Review for Sangamo Therapeutics' Second Quarter of 2025
Sangamo Therapeutics (SGMO) has announced its Q2 2025 earnings, missing both EPS and revenue estimates. The company reported revenue of approximately $18.3 million, significantly below the consensus estimate of $31.68 million. The net loss for the quarter was $20 million or about 8 cents per share.
The revenue shortfall can be attributed to delayed payments related to Sangamo's Eli Lilly capsid licensing deal. Despite the miss, the company highlights ongoing pipeline progress and partnership milestones, which may support future growth.
Key details include: - Revenue: $18.3M vs. $31.68M estimated. - EPS (loss): -$0.08 per share, reflecting a continuing net loss environment. - Revenue shortfall attributed to delayed payments, not fundamental operational decline. - Operating expenses remained stable or slightly improved, with increased focus on cost control.
Over the last 2 years, Sangamo Therapeutics has beaten revenue estimates 25% of the time and EPS estimates 38% of the time.
Looking ahead, Sangamo will announce its Q3 earnings on November 7th, after market close. The company's Q1 2025 Earnings Call is scheduled for a later date.
In other news, Sangamo Therapeutics has seen a rise following trial data for its Fabry disease therapy. Additionally, RFK Jr. is aiming to accelerate the approval process for rare disease drugs, with an updated news.
For those interested in Sangamo Therapeutics' performance, Seeking Alpha has provided a Quant Rating for the company.
The revenue shortfall in Q2 2025 can be linked to delayed payments from Sangamo's Eli Lilly capsid licensing deal, but the company remains optimistic about its ongoing pipeline progress and partnership milestones in the realm of future business growth and investing opportunities. Despite missing revenue and EPS estimates, Sangamo Therapeutics has shown promising performance in certain areas, such as cost control, as reflected in their operating expenses remaining stable or showing improvements.
